Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis G Paz-Ares, Mikhail Vladimirovich Dvorkin, Yuanbin Chen et al. · The Lancet · 2019
Cited by 2,279 works. doi:10.1016/s0140-6736(19)32222-6
Authors
- Luis G Paz-Ares
- Mikhail Vladimirovich Dvorkin
- Yuanbin Chen
- Niels Reinmuth
- Katsuyuki Hotta
- Dmytro V. Trukhin
- Galina Statsenko
- Maximilian Johannes Hochmair
- Mustafa Özgüroğlu
- Jun Ho Ji
- Artem Poltoratskiy
- Santiago Ponce
- Francesco Verderame
- Libor Havel
- Igor Bondarenko
- Andrzej Każarnowicz
- György Losonczy
- Nikolay Vladimirov Conev
- Jon M. Armstrong
References
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
- Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody
- Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer
- Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Small cell lung cancer: Where do we go from here?
- Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data